옵션 체인은 다양한 행사가격과 만기일에 대한 Precision Optics Corp의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Precision Optics Corp에 대한 시장 심리를 평가합니다..

Precision Optics Corp (NASDAQ:POCI) 주식, 옵션 체인

Precision Optics Corp

Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy customers' specific requirements. In addition, the company manufactures and sells components and assemblies specially designed for industrial and military use. The company earns the majority of its revenue from the United States.

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp Inc

Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) reported quarterly losses of $(0.30) per share. This is a 500 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $4.19 million in sales this quarter. This is a 20.16 percent decrease over sales of $5.24 million the same period last year.

Earnings

News

POCI

Precision Optics Corp Q3 EPS $(0.30) Down From $(0.05) YoY, Sales $4.19M Down From $5.24M YoY

ACOG

AENT

AIRI

AMAT

AREN

BABA

BCLI

BEKE

BFRI

BHST

BIRK

BLIN

BNZI

BRAG

BTBT

BTDR

CAVA

CSIQ

CYCC

DFLI

DOCS

DTIL

DTST

DUOT

EDAP

EDBL

FLNT

FTLF

GAMB

GAME

GLOB

GORV

GOSS

GSX Techedu Inc. American Depositary Shares

GOTU

HAFN

IMCC

INKT

IVVD

JAGX

KORE

KPLT

KULR

LFWD

LGCY

LMFA

LPTH

LTRN

MITQ

MRSN

NICE

NRXP

NTES

NVVE

NXPL

OMER

ONDS

ORGN

PAVM

PHGE

PIII

PLBY

PPSI

PVLA

QUBT

RIME

RNXT

ROLR

SANW

SCWO

SIDU

SNYR

SOBO

SPCE

SRTS

SRXH

SWKH

TIVC

TLSI

TRAK

TSHA

TSSI

Earnings Scheduled For May 15, 2025

<h3>Gainers</h3>
<ul>
<li>Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) stock rose 21.4% to $4.7 during Monday's after-market session. The company's market cap stands at $35.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 15.01% to $0.25. The market value of their outstanding shares is at $11.0 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares rose 9.52% to $0.69. The company's market cap stands at $16.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares moved upwards by 8.26% to $4.06. The market value of their outstanding shares is at $2.6 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) shares moved upwards by 7.83% to $0.34. The company's market cap stands at $19.8 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock increased by 7.61% to $8.34. The market value of their outstanding shares is at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 29.9% to $0.75 during Monday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) stock fell 16.07% to $141.77. The company's market cap stands at $4.0 billion. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock declined by 13.67% to $0.56. The company's market cap stands at $98.4 million. </li>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) stock declined by 12.11% to $1.38. The market value of their outstanding shares is at $9.6 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 10.42% to $0.21. The company's market cap stands at $1.3 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock decreased by 9.31% to $1.17. The market value of their outstanding shares is at $12.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BCAB

BSGM

CRIS

GOVX

HCTI

KRYS

MCRB

NAOV

NERV

VERO

YCBD

12 Health Care Stocks Moving In Monday's After-Market Session

<ul>
<li>$3.1 million of new orders received during the current calendar year</li>
<li>$6.6 million customer program backlog expected to be delivered over next 12 months
<ul>
<li>$3.9 million of additional commitments expected to be received for calendar 2026 &nbsp;</li>
</ul>
</li>
</ul>

Contracts

Precision Optics Enters Into Main Purchase Agreement With Aerospace Customer And Expands Program Backlog To $6.6M

Precision Optics Corporation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has entered into securities purchase agreements with institutional and accredited investors for the purchase and sale of 1,272,500 shares of the Company's common stock, par value $0.01 per share, pursuant to a registered direct offering at a purchase price of $4.00 per share, resulting in gross proceeds of approximately $5.1 million, and expected net proceeds of approximately $5.0 million after deducting offering expenses. The Company intends to use the net proceeds from the offering to repay certain indebtedness, expand its facilities to support expected growth and related general working capital purposes.
The closing of the offering, which was led by existing stockholders, is expected to occur on or about February 21, 2025, subject to the satisfaction of customary closing conditions.

Offerings

Precision Optics Prices $5.1M Offering Of 1,272,500 Shares Of Common Stock At A Price Of $4.00 Per Share

Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) reported quarterly losses of $(0.15) per share. This is a 15.38 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $4.53 million in sales this quarter. This is a 6.16 percent decrease over sales of $4.82 million the same period last year.

Precision Optics Corp Q2 EPS $(0.15) Down From $(0.13) YoY, Sales $4.53M Down From $4.82M YoY

ABNB

AGIO

ALNY

APDN

ATUS

AVNT

BENF

BFAM

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

COIN

CROX

CYBR

DDOG

DKNG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

NTWK

NVMI

Earnings Scheduled For February 13, 2025

Precision Optics Secures Initial $340K Production Order From A Large, Global Medical Device Company For New Single-use Ophthalmic Endoscope

Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) reported quarterly losses of $(0.21) per share. This is a 162.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $4.20 million in sales this quarter. This is a 2.88 percent decrease over sales of $4.32 million the same period last year.

Precision Optics Corp Q1 EPS $(0.21) Down From $(0.08) YoY, Sales $4.20M Down From $4.32M YoY

Comments

Precision Optics Corp

Precision Optics Corp (POCI) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌